
Feature|Articles|August 17, 2026
Competing Vaccine Schedules Leave Pharmacists Navigating Confusion
Author(s)Ashley Gallagher, MA
A year of ACIP turnover, schedule changes, and lawsuits has fractured US vaccine guidance—and tied pharmacists' scope and billing to a moving target.
Advertisement
Advertisement
For more than 60 years, the Advisory Committee on Immunization Practice (ACIP), a committee of scientific and health experts, has driven federal vaccine recommendations later adopted by the CDC.¹ Since United States Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr was sworn in on February 13, 2025, that process has been upended through committee turnover, unilateral recommendation changes, ongoing litigation, and, most recently, competing vaccine schedules from federal agencies and nonfederal medical societies alike.
Related to this article

Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.

Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.

Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.

Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.

Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.

A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.

A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
Advertisement
Advertisement

